Evidence map›Paper›PMID 21765856›Full record

ArticleExpert review of endocrinology & metabolism2011

Estrogen action and prostate cancer.

Jason L Nelles, Wen-Yang Hu, Gail S Prins

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert review of endocrinology & metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 6 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 6 syntheses or guidelines pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jason L NellesDepartment of Urology, University of Illinois at Chicago, 820 South Wood Street, MC 955, Chicago, IL 60612, USA.
Wen-Yang Hu
Gail S Prins
University of Illinois Chicago · US

Funding

Epigenetic Basis for Prostate Carcinogenesis following Early Estrogenic ExposuresR01ES015584 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HO, SHUK-MEI, PRINS, GAIL S · 2008 to 2012
$3.1M
Development Estrogenization of the Rat Prostate GlandR01DK040890 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PRINS, GAIL S · 1996 to 2010
$2.9M
Developmental Exposure to Low-dose Bisphenol A and Human Prostate Cancer SusceptiRC2ES018758 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HO, SHUK-MEI, PRINS, GAIL S · 2009 to 2010
$1.9M
NIDDK NIH HHS R01 DK040890NIEHS NIH HHS R01 ES015584NIEHS NIH HHS RC2 ES018758
6 · The paper itself

Abstract

Early work on the hormonal basis of prostate cancer focused on the role of androgens, but more recently estrogens have been implicated as potential agents in the development and progression of prostate cancer. In this article, we review the epidemiological, laboratory and clinical evidence that estrogen may play a causative role in human prostate cancer, as well as rodent and grafted in vivo models. We then review recent literature highlighting potential mechanisms by which estrogen may contribute to prostate cancer, including estrogenic imprinting and epigenetic modifications, direct genotoxicity, hyperprolactinemia, inflammation and immunologic changes, and receptor-mediated actions. We discuss the work performed so far separating the actions of the different known estrogen receptors (ERs), ERα and ERβ, as well as G-protein-coupled receptor 30 and their specific roles in prostate disease. Finally, we predict that future work in this field will involve more investigations into epigenetic changes, experiments using new models of hormonal dysregulation in developing human prostate tissue, and continued delineation of the roles of the different ER subtypes, as well as their downstream signaling pathways that may serve as therapeutic targets.

Identifiers

PMID21765856
PMCPMC3134227
OpenAlexW2123529223

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.